We read with interest recent publications (1, 2) regarding the precipitation of protein from multiple myeloma serum causing spurious results. We noted low results (in some cases 20 g/L) for total protein in serum from three myeloma patients, all 1gM type, as analyzed in the sc continuous-flow analyzer (Technicon Instruments Inc., Tarrytown, NY) when compared with a manual biuret method (3) involving reagents as used in the SMAC. These sera caused the formation of a precipitate when mixed with pre-dilution fluid (de- was heavy enough to block the pre-dilution system, but this was rare. We conclude that the error is due to a preferential sampling of fluid rather than precipitate from the SMAC pro-dilution system. Analyzing these specimens diluted (one part specimen to two parts 150 mmoIJL NaC1) gave results comparable with those by the manual protein method.
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We tested a series of 50 sera containing paraproteins of different types by mixing 0.1 mL of serum with 0.5 mL of pro-dilution fluid and looked for turbidity in the resulting solution. Precipitation was peculiar to 1gM type paraproteins, although not all reacted in this way.
We investigated the effect of this precipitate on results for other analytes, in particular those without dialysis-total Lauren2i also found bands unique to CSF as well as the bands common to both CSF and serum. This result is quite different from their own, and it gives no support to their contention regarding interpretation of non-unique CSF oligoclonal bands. Recently an abstract has appeared (3) that also suggests that a minority of MS patients may have identical band patterns in both CSF and serum. However, there is insufficient information in the abstract for one to evaluate these findings fully.
Oligoclonal bands are present in the CSF of over 90% of MS patients (4) and, although not specific for this disease, their presence can be very helpful in making the diagnosis. The criteria of the Poser committee (5) are currently the best accepted for a definitive diagnosis of MS for research purposes. From these criteria, if oligoclonal bands are to be used to support a clinical diagnosis of MS, then at least some of the bands must be present in the CSF only. In clinical practice, however, a few patients will be diagnosed by the neurologist as having MS, even though they do not meet all the criteria (5).
Using agarose gel IEF followed by immunofl.xation and silver staining for both CSF and serum from patients with possible MS, we have found 34 patients with multiple IgG bands in their CSF. These patients could be divided into three groups on the basis of their IEF findings. Group I (eight patients) had no bands in their serum. Group H (17 patients) had some bands common to both serum and CSF but also unique CSF bands. Group ifi (nine patients) had only bands of identical mobility in CSF and serum. On followup of the patients' medical records, nine had a final diagnosis of definite MS, four were probable MS, and 21 not MS. All of the patients with a clinical diagnosis of definite or probable MS were in groups I or II; that is, they had oligoclonal bands unique to the CSF. Patients with diagnoses other than MS could have had any of the three patterns.
For oligoclonal bands to be diagnostically significant in MS, current practice requires that bands unique to the CSF be present. The two recent reports
